Literature DB >> 8808122

Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage.

J van de Wetering1, R G Westendorp, J G van der Hoeven, B Stolk, J D Feuth, P C Chang.   

Abstract

Heparin is the most widely used anticoagulant in continuous renal replacement procedures but little is known about the balance between filter coagulation and patient hemorrhage during treatment. Filter survival and hemorrhagic complications during 240 filter periods in 78 critically ill patients, treated with continuous arteriovenous hemofiltration and hemodiafiltration, were studied for this article. The crude incidence of filter coagulation was 17.7 +/- 2.5 (mean +/- SE) per 1000 h at an activated partial thromboplastin time (APTT) of 15 to 35 s, as determined in systemic blood samples. The incidence of filter coagulation gradually decreased to 9.0 +/- 2.7 per 1000 h at an APTT of 45 to 55 s (P = 0.031). The crude incidence of patient hemorrhage was 2.9 +/- 1.0 per 1000 h at an APTT of 15 to 35 s and increased almost threefold to 7.4 +/- 2.4 per 1000 h when the APTT was 45 to 55 s (P = 0.009). There was no difference in filter survival between treatment with hemofiltration only and hemodiafiltration. Mean survival of acrylonitrile filters (33.8 +/- 4.3) was significantly lower compared with the survival of polyamide filters (104.1 +/- 14.4 h, P = 0.003). After adjustment for the type of the filter, mean arterial blood pressure, and platelet count, the risk for filter coagulation decreased 25% (relative risk, 0.77; 95% confidence interval [CI], 0.62 to 0.96) for every 10-s increase in APTT. At the same time, the risk for patient hemorrhage increased 50% (relative risk, 1.57; 95% CI, 1.43 to 1.72). The occurrence of filter coagulation or hemorrhages were not correlated with the administered dose of heparin. Concurrent use of coumarin derivatives had a positive effect on filter survival, without increasing the overall incidence of hemorrhages. It was concluded that the systemic APTT is a good predictor of the risk for filter coagulation and patient hemorrhage. Safety and efficacy of heparin therapy seems optimal at an APTT between 35 and 45 s.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808122     DOI: 10.1681/ASN.V71145

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  35 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

Review 2.  Anticoagulation techniques in apheresis: from heparin to citrate and beyond.

Authors:  Grace Lee; Gowthami M Arepally
Journal:  J Clin Apher       Date:  2012-04-24       Impact factor: 2.821

Review 3.  Continuous Renal Replacement Therapy: Who, When, Why, and How.

Authors:  Srijan Tandukar; Paul M Palevsky
Journal:  Chest       Date:  2018-09-25       Impact factor: 9.410

4.  Regional citrate anticoagulation--a safe and effective procedure in pediatric apheresis therapy.

Authors:  Martin Kreuzer; Thurid Ahlenstiel; Nele Kanzelmeyer; Jochen H H Ehrich; Lars Pape
Journal:  Pediatr Nephrol       Date:  2010-10-21       Impact factor: 3.714

5.  Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration.

Authors:  Shigehiko Uchino; Nigel Fealy; Ian Baldwin; Hiroshi Morimatsu; Rinaldo Bellomo
Journal:  Intensive Care Med       Date:  2003-02-08       Impact factor: 17.440

6.  Citrate anticoagulation in pediatric continuous venovenous hemofiltration.

Authors:  Nahum Elhanan; Peter Skippen; Gabrielle Nuthall; Gordon Krahn; Michael Seear
Journal:  Pediatr Nephrol       Date:  2003-12-11       Impact factor: 3.714

Review 7.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

8.  Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.

Authors:  Alexander Zarbock; Mira Küllmar; Detlef Kindgen-Milles; Carola Wempe; Joachim Gerss; Timo Brandenburger; Thomas Dimski; Bartosz Tyczynski; Michael Jahn; Nils Mülling; Martin Mehrländer; Peter Rosenberger; Gernot Marx; Tim Philipp Simon; Ulrich Jaschinski; Philipp Deetjen; Christian Putensen; Jens-Christian Schewe; Stefan Kluge; Dominik Jarczak; Torsten Slowinski; Marc Bodenstein; Patrick Meybohm; Stefan Wirtz; Onnen Moerer; Andreas Kortgen; Philipp Simon; Sean M Bagshaw; John A Kellum; Melanie Meersch
Journal:  JAMA       Date:  2020-10-27       Impact factor: 56.272

9.  Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study.

Authors:  Michael Joannidis; Jordan Kountchev; Markus Rauchenzauner; Nicola Schusterschitz; Hanno Ulmer; Andreas Mayr; Romuald Bellmann
Journal:  Intensive Care Med       Date:  2007-06-12       Impact factor: 17.440

10.  Citrate versus non-citrate anticoagulation in continuous renal replacement therapy: Results following a change in local critical care protocol.

Authors:  Samina R Chowdhury; Tom Lawton; Aaqid Akram; Robert Collin; James Beck
Journal:  J Intensive Care Soc       Date:  2016-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.